AB0718 Prevalence of risk factors for fractures in axial spondyloarthritis: a systematic review

Abstract

BackgroundSpinal fractures occur more than expected in axial spondyloarthritis (Ax-Sp). However, it is not totally clear whether fracture risk depends solely on biomechanical problems of the spondyloarthritic spine or whether the prevalence of risk factors for fracture is larger than expected in these patients.ObjectivesTo describe the prevalence of risk factors for osteoporotic fractures (both axial and peripheral) in Ax-Sp.MethodsA systematic literature search was conducted. Medline, Embase and Cochrane Library databases were searched with a sensitive strategy including type of study and synonyms of Ax-Sp. All contemporary cross sectional studies or baseline results from representative cohorts of Ax-Sp published between January 2006 and 2016 were selected for detailed review. Only studies that fulfilled a minimum quality for survey data were included. Data on bone mineral density, prevalence of osteoporosis, and risk factor for fractures in Ax-Sp patients were collected.ResultsAfter screening 3597 titles and abstracts, only 43 studies (34 cross-sectional, 3 prospective and 6 retrospective) were reviewed in detail. Of these, 20 studies compared Ax-Sp patients with a control group, either healthy individuals (17 studies) or subjects with other diseases (6 studies). Reported prevalence of osteoporosis varied from 2% to 39.6%. Alcohol intake (58–61%), use of corticosteroids (11.7–67%), and 25-OH vitamin D deficit (26–76%) were unexpectedly high in Ax-Sp patients. All other factors were within expected frequencies for a not too old population.ConclusionsOur systematic review found that alcohol intake, steroid use and 25-OH-vitamin D deficit should be taken into account when assessing comorbidity in Ax-Sp in order to avoid excess fractures.Acknowledgementsthis project was funded by Merck Sharp & Dohme of Spain.Disclosure of InterestNone declared

Combined virgin coconut oil and tocotrienol-rich fraction protects against bone loss in osteoporotic rat model

“…Estrogen replacement therapy (ERT) is the primary treatment and prevention of postmenopausal osteoporosis [10]. Either estrogen alone or in combination with progesterone may prevent bone loss after menopause.…”